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Variants in two genes of the IL-23 receptor (R) pathway have recently been shown to be associated with psoriasis
vulgaris (PV). We were interested whether the risk conferred by these variants differs between psoriatic skin
and joint disease. Four variants of the IL12B and IL23R genes were analyzed in 1,114 PV patients, 748 patients
with psoriatic arthritis (PA) and 937 healthy controls before and after stratification for the major psoriasis risk
allele at psoriasis susceptibility locus 1 (PSORS1). For both PA and PV, we detected the strongest association with
two IL12B single-nucleotide polymorphisms and the corresponding haplotype as reflected by minimal P-values
of 107 and highest odds ratios of 1.50 (1.28–1.75) for rs6887695 in PA patients and 1.50 (1.27–1.76) for rs3212227 in
the PV cohort, respectively. For IL23R, only rs11209026 showed an association. The results remained significant
after correction for multiple testing. No difference was observed after stratification for the PSORS1 risk allele.
While confirming recent reports on variants of the IL-23R pathway as susceptibility factors for PV, our study is
the first to extend analysis of both genes to PA. However, our results indicate that these variants are not specific
risk factors for arthritis, but relevant for susceptibility to psoriasis in general.
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INTRODUCTION
About 30% of patients with psoriasis vulgaris (PV), a chronic
inflammatory disorder of the skin, develop an inflammatory
joint disease, designated as psoriatic arthritis (PA); (Gladman
et al., 2005). As known from family studies, there is
considerable contribution of genetic factors to PA. In the
pursuit of genetic factors causing PA, one genome-wide
linkage scan in Icelandic families and multiple genetic
studies in various populations mainly of European descent
were performed. In the genome-wide linkage study, a
susceptibility locus on chromosome 16q21 was identified
with convincing evidence for paternal imprinting (Karason
et al., 2003). Owing to observations of a higher than
coincidental rate of patients with co-occurrence of Crohn’s
disease (CD) with psoriasis (Yates et al., 1982; Lee et al.,
1990), common genetic factors have been postulated.
Interestingly, the PA locus at 16q21 is in the vicinity of the
inflammatory bowel disease-causing gene CARD15 at
susceptibility locus IBD1 (Hugot et al., 2001). But variants
of CARD15 do not seem to be disease-causing in PA
(Ho et al., 2005; Lascorz et al., 2005; Jenisch et al., 2006).
In contrast, at IBD5 (chromosome 5q31) in the organic cation
transporter genes, a haplotype of two single-nucleotide
polymorphisms (SNPs) as well as a promoter polymorphism
—both previously identified to affect gene functions in CD
(Peltekova et al., 2004)—were associated with PA in British
patients (Ho et al., 2005). Very recently an association of
psoriasis with several susceptibility variants identified for CD
could be shown (Wolf et al., 2007).
Variants in genes at chromosomes 1p31 and 5q33 coding
for IL-23 receptor and its ligand IL-12b (¼ IL-12 subunit p40),
respectively, have also been shown to be associated with CD
(Duerr et al., 2006). After a preliminary study of association of
one IL12B variant with PV (Tsunemi et al., 2002), overlap of
all these variants in genetic contribution to CD and to skin
manifestation of PV was recognized only recently (Capon
et al., 2007; Cargill et al., 2007; Chang et al., 2007). In
contrast, in a small cohort of PA patients no association with
IL12B variants was found (Chang et al., 2007), whereas an
association of IL23R variants with ankylosing spondylitis has
been described (Burton et al., 2007). In an effort to identify
concordances and deviations of genetic factors for PsV and
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PA, we analyzed two variants of IL12B (rs3212227 and
rs6887695) and of IL23R (rs7530511 and rs11209026),
respectively, in a case–control study of 748 PA patients,
1,114 PV patients, and 937 healthy controls. To analyze,
whether there might be an interaction with the major genetic
risk factor of psoriasis, we stratified the cohorts for psoriasis
risk allele at psoriasis susceptibility locus 1 (PSORS1). In
addition, we carried out a stratification of the PA group for
spinal involvement.
RESULTS
For both phenotypes, we observed strongest association with
the two SNPs and the corresponding haplotype of the IL12B
gene (Table 1), minimal P-values were in the range of 107 at
single SNP level, corresponding odds ratios (ORs) 1.50. Exact
values for the most strongly associated SNPs were
Po4.72 107 and corresponding OR¼ 1.50 (1.28–1.75)
for rs6887695 in the PA study (PV: OR¼1.43 (1.24–1.64))
and 9.67107 and 1.50 (1.27–1.76) for rs3212227 in the
PV study (PA: OR¼1.48 (1.24–1.78)), respectively. At
haplotype level, P-values for both PA and PV were in the
order of magnitude of 106 for the risk haplotype consisting of
alleles A (rs3212227) and G (rs6887695), with corresponding
ORs of 1.44 (1.24–1.68) in PA and of 1.38 (1.21–1.58) in PV
(Table 2). Compared to these results, the effect for
rs11209026 was slightly weaker for the PV phenotype and
considerably weaker in the case of the PA study (Table 1),
whereas no evidence for an association was observed with
allele C of rs7530511. Association of the IL23R haplotype
consisting of alleles C (rs7530511) and G (rs11209026) was
considerably weaker with regard to both phenotypes
(Table 2). All significant P-values remained significant after
correction for multiple testing with permutation analysis.
After stratification for the PSORS1 risk allele in PV patients
and control probands, P-values for the two single SNPs and
the risk haplotype of IL12B were considerably lower in
noncarriers of the PSORS1 risk allele—range of 104–105—
than in carriers, whereas in contrast, corresponding P-values
in the study group of PA patients were similar in carriers and
noncarriers of the PSORS1 risk allele (data not shown). A
w2-test for SNP rs3212227 in PV patients, performed to
identify a possible difference between PV patients carrying or
not carrying the PSORS1 risk allele, however, yielded no
significant differences, though. Similarly, after stratification of
PA patients for spinal involvement (spondylitis or sacroiliitis),
no difference in the strength of association between the two
groups was observed (data not shown).
DISCUSSION
Our results for PV confirm previous studies that variants in
IL12B and IL23R genes are susceptibility factors for PV
(Capon et al., 2007; Cargill et al., 2007; Chang et al., 2007).
Furthermore, our current association findings as well as
the previous ones show a more consistent and stronger
Table 1. Allele frequencies of the four variants in patients and controls and results of v2-statistics
PV PA
Gene
SNP rs -
number Allele n (%) v2 P-value
OR (95 %
confidence
interval) Controls n (%) n (%) v2 P-value
OR (95 %
confidence
interval)
IL-23R rs7530511 C 1,928 (87.1) 0.14 NS NA 1,614 (86.7) 1,306 (88.4) 2.12 NS NA
T 286 (12.9) 248 (13.3) 172 (11.6)
IL-23R rs11209026 G 2,125 (96.1) 22.23 2.42 106 1.94 (1.47–2.56) 1,715 (92.8) 1,396 (95.4) 9.33 0.002 1.59 (1.18–2.15)
A 85 (3.9) 133 (7.2) 68 (4.6)
IL-12B rs3212227 T 1,876 (85.0) 23.99 9.67 107 1.50 (1.27–1.76) 1,445 (79.1) 1,243 (84.9) 18.09 2.10 105 1.48 (1.24–1.78)
G 330 (15.0) 381 (20.9) 221 (15.1)
IL-12B rs6887695 G 1,689 (76.4) 24.96 5.84 107 1.43 (1.24–1.64) 1,285 (69.4) 1,117 (77.2) 25.37 4.72 107 1.50 (1.28–1.75)
C 523 (23.6) 567 (30.6) 329 (22.8)
NA, not applicable; NS, not significant; OR, odds ratio; PA, psoriatic arthritis; PV, psoriasis vulgaris; SNP, single-nucleotide polymorphism.
Table 2. Frequencies of risk-conferring haplotypes in patients and controls and results of v2-statistics
PV PA
Gene
Associated
haplotype n (%) v2 P-value
OR (95%
confidence interval) Controls n (%) n (%) v2 P-value
OR (95%
confidence interval)
IL-23R C_G 1,828 (83.2) 8.98 0.003 1.27 (1.09–1.49) 1,461 (79.5) 1,217 (83.8) 10.03 0.002 1.33 (1.12–1.60)
IL-12B T_G 1,587 (72.4) 22.13 2.56106 1.38 (1.21–1.58) 1,183 (65.5) 1,042 (73.3) 22.45 2.16 106 1.44 (1.24–1.68)
OR, odds ratio; PA, psoriatic arthritis; PV, psoriasis vulgaris.
Order of SNPs in corresponding haplotypes: rs7530511–rs11209026 for IL23R and rs3212227–rs6887695 for IL12B.
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association for IL12B than for IL23R variants. It cannot be
excluded, though, that other IL23R variants might be more
strongly associated and thus more relevant for psoriasis as the
gene is split in three larger blocks of high linkage
disequilibrium. To our knowledge, our study is the first to
analyze variants of both genes of the IL23R pathway for the
PA phenotype. In contrast to a previous smaller study that
found no association of IL12B variants with PA in 102
patients, our large study showed strong evidence for
association of PA with variants in both genes, IL12B and
IL23R. As our association findings for IL12B SNPs and the
corresponding haplotype are in a similar range as in the
comparably large PV group, we suggest that the variants do
confer susceptibility to psoriasis in general, but are not
specific risk factors for arthritis. As the risk alleles for PA are
frequent alleles, they can be found on several haplotypes.
Therefore, the chance to identify alternative risk alleles is
limited. Furthermore, in both genes, the risk alleles were not
only common in our patient groups, but also fairly common
in control individuals. More common alleles result in
comparably lower ORs; it has been extensively shown, for
example in CD that many single risk factors confer only small
relative risk to develop disease. This finding also corresponds
to the hypothesis called common disease–common variant
hypothesis.
To determine whether association to variants in the IL23R
pathway is independent of the major psoriasis risk factor, the
PSORS1 risk allele, we stratified for a risk haplotype that is in
strong linkage disequilibrium with HLA-Cw*0602 allele, the
risk allele for psoriasis. In both the patient groups, stratifica-
tion for this risk allele did not greatly affect association
findings suggesting that both the risk factors act indepen-
dently.
Interestingly, our results indicate that in PA risk alleles of
the IL-23R pathway are not relevant for development of
spinal symptoms suggesting that previous findings in ankylos-
ing spondylitis are either disease-specific or confer a more
general susceptibility to inflammatory diseases.
In CD, mainly variants of the IL23R gene and to a lesser
extent variants of the IL12B gene have been analyzed, but it is
striking that association with the so far analyzed IL23R gene
variants is less consistent in patients with PV and PA than in
studies of CD. In general though, our study provides evidence
that there is an overlap in susceptibility factors not only of CD
and PV, but also of CD and PA, furthermore of ankylosing
spondylitis with PV and PA.
In summary, our results confirm recent reports of variants
of two genes of the IL-23R pathway as susceptibility factors
for PV and extend these findings to PA. Our data indicate that
these variants do confer susceptibility to psoriasis in general
and are not specific risk factors for arthritis.
MATERIALS AND METHODS
The PA patients were of German descent and fulfilled the recent
classification of psoriatic arthritis study criteria (Taylor et al., 2006).
Recruitment and clinical evaluation were performed as previously
described in a smaller subset of this study group (Lascorz et al.,
2005). The mean (standard deviation) age of onset for PsV was
28.8±13.3 years; 61.8% of the patients were male. For 79% of the
patients, the diagnosis of PA was made 3 years or more before
recruitment and 93% of patients had a skin involvement 3 years or
more before recruitment. Peripheral joint involvement was detectable
in the majority of cases (713, or 95.3%); this was oligoarticular in 166
patients and polyarticular in 544 (22.2 and 72.7% of the entire
cohort, respectively). Diagnosis of spinal involvement was based on
symptoms of inflammatory back pain, characteristic clinical signs of
restricted vertebral movement and/or sacroiliac pain upon physical
examination, and a subsequent confirmation by radiographic signs of
either sacroiliitis and/or spondylitis. Spinal involvement was ob-
served in 156 patients, accounting for 20.9% of the PA cohort. In
these patients, sacroiliits or spondylitis or both were partly associated
with concomitant peripheral joint disease.
The 1114 single PV patients were recruited through dermatology
clinics at three psoriasis rehabilitation hospitals and at three
university hospitals. An early onset form of psoriasis (type I) was
diagnosed in all but 75 patients. The medium age of onset was
23.2±11.9 and 21.4±9.5 years in type I patients. The majority of
patients suffered from plaque type of PV. We excluded all patients
with signs of PA until the time of recruitment when medium age was
48.2±13.4 years. A total of 62% of patients were male.
The 937 control probands had no PV and no history or signs of
inflammatory joint disease at the time of recruitment, when their
mean age was 31.6±10 years. All were German (white) healthy
blood donors. A total of 58% of probands were male.
The studies were approved by the ethical committees of the
University of Erlangen-Nuremberg and of the University of Mu¨nster.
Written informed consent was obtained from each patient and
control proband prior to enrollment. The investigations were
conducted according to the Declaration of Helsinki Principles.
The four SNPs—rs3212227 and rs6887695 of the IL12B gene and
rs7530511 and rs11209026 of the IL23R gene—were genotyped
with 20 ng of genomic DNA as previously described (Lascorz et al.,
2005). All four assays were purchased as TaqMan SNP Genotyping
Assays (Applied Biosystems, Foster City, CA) and genotyped
following the manufacturer’s instructions. The genotyping rate for
single SNPs ranged from 98.3 to 99.4%. Hardy–Weinberg equili-
brium was tested and observed for each SNP in both, the control and
patient groups. Genotypes for SNPs were verified by direct
sequencing in a set of 24 randomly chosen probands.
For single SNPs and haplotypes, we calculated w2-tests based on
the number of alleles in (subsets of) the case–control groups. For each
test, 1,000 permutations were performed with Haploview (Barrett
et al., 2005) to reassure that significant results were not false positive.
OR and their confidence intervals were determined for single SNP
alleles and haplotypes with final P-values of o0.05. In the control
and patient groups, haplotypes within the blocks were calculated
with PHASE (Stephens et al., 2001) and Haploview (Barrett et al.,
2005).
For stratification for the PSORS1 risk allele, we used an estimate
for the PSORS1 risk allele based on previous data in the literature
and HapMap data which was shown to segregate with the disease in
270 small families and 375 cases and 376 controls each of German
origin (unpublished data). This haplotype was genotyped using three
SNPs (rs1576, rs130076, and rs2523619) with TaqMan assays as
described above; haplotypes were calculated with PHASE (Stephens
et al., 2001). Frequencies of the three SNP risk haplotype ‘‘GTC’’ are
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given in Table 3. In addition to the stratification for PSORS1, we
stratified PA patients also for spinal involvement.
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